This is a regulatory disclosure made by AstraZeneca Pharma India Limited to the BSE Limited and the National Stock Exchange of India Limited, pursuant to Regulation 30(7) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
The disclosure provides an update on a demand notice dated July 27, 2026, issued by the National Pharmaceutical Pricing Authority (NPPA). The notice was for alleged overcharging under the Drugs (Prices Control) Order, 2013, specifically concerning the drug Betaloc-50 (Metoprolol 50 mg tablets).
The key update is that the Hon'ble High Court of Delhi, vide its order dated August 24, 2026, has stayed the operation of the NPPA's demand notice. This stay is effective until the next date of hearing, which is February 10, 2027. The stay is conditional and subject to the Company depositing 15% of the total amount mentioned in the Demand Notice with the Registrar General of the Delhi High Court. The company states it is taking necessary steps in this connection.
The nature of the alleged violation, as detailed in Annexure A, is that the NPPA claims the company sold/marketed Betaloc-50 tablets at a Maximum Retail Price (MRP) higher than the ceiling price notified under the DPCO, 2013. The NPPA alleged the company failed to implement the revised ceiling price based on notifications S.O. 644(E) dated March 2, 2016, and S.O. 1352(E) dated June 2, 2016, on stocks available in the market. This alleged overcharging occurred during the period of June to July 2016. The NPPA's demand was for the recovery of the overcharged amount along with applicable interest.
The case reference in the Delhi High Court is W.P.(C) 12314/2026 & CM APPL. 57158-59/2026, titled AstraZeneca Pharma India Limited v. National Pharmaceutical Pricing Authority, Department of Pharmaceuticals & Anr.
The quantifiable financial impact of the court's interim order is an immediate requirement to deposit 15% of the amount mentioned in the NPPA's Demand Notice. The exact monetary value of the total demand is not quantified in this disclosure.
This communication is signed by Tanya Sanish, Company Secretary & Compliance Officer, on behalf of AstraZeneca Pharma India Limited.